Trade Mark Journal No.2025/042 17 October 2025
WO0000001878558 (5,42)
Office of origin: United States of America
Date of International Registration:14 May 2025
Date of designation in the UK:
14 May 2025
International priority date claimed: 16 November 2024
(United States of America)
(98857292)
- Class 5
- Therapeutic pharmaceuticals for the treatment of neuro-psychological disorders, autism, metabolic and inflammatory diseases, obesity and metabolic disorders, Prader-Willi syndrome, and hypothalamic obesity; therapeutic pharmaceuticals for cancer treatment and management; abuse-deterrent pharmaceutical preparations for treatment of neuro-psychological disorders, autism, metabolic and inflammatory diseases, obesity and metabolic disorders, Prader-Willi syndrome, and hypothalamic obesity.
- Class 42
- Medical and scientific research and development in the fields of diagnosis and treatment of neuro-psychological disorders, autism, metabolic and inflammatory conditions, obesity and metabolic disorders, Prader-Willi syndrome, and hypothalamic obesity; providing medical and scientific research information in the fields of neuro-psychological disorders, autism, metabolic and inflammatory diseases, obesity and metabolic disorders, Prader-Willi syndrome, and hypothalamic obesity; medical and scientific research, namely, conducting clinical trials for others for pharmaceuticals, drug development, and therapeutic applications in the fields of neuro-psychological disorders, autism, metabolic and inflammatory diseases, obesity and metabolic disorders, Prader-Willi syndrome, and hypothalamic obesity; clinical research in the field of neuro-psychological disorders, autism, metabolic and inflammatory diseases, and obesity and metabolic disorders, Prader-Willi syndrome, and hypothalamic obesity.
AARDVARK THERAPEUTICS, INC.
Representative: Elise Wu Paul Hastings LLP, 1117 S California Ave, Palo Alto CA 94304, UNITED STATES OF AMERICA